新型冠状病毒感染后肺纤维化病变诊治进展

doi:10.3877/cma.j.issn.1674-1358.2023.05.002

新型冠状病毒（SARS-CoV-2）感染引起了全球出现大量急性新型冠状病毒肺炎（COVID-19）患者，随着病程演变，部分患者在急性期过后出现肺纤维化问题逐渐突显。目前学者们称之为新型冠状病毒感染后肺纤维化（PCPF）。由于SARS-CoV-2不断突变及全球医疗水平大相径庭，PCPF发生率及诊治亦存在差异。肺纤维化程度显著影响患者临床表现，患者症状迁延，需要大量医疗资源及长期的专业照护。目前PCPF诊断依靠临床结合CT及肺功能检查，治疗依靠既往其他肺纤维化疾病的治疗经验，缺乏统一、规范的处置方案。尽管许多学者为此开展研究，但仍没有十分有效的治疗方法。本文就PCPF发病及其机制进行概述，重点回顾相关诊断及治疗研究进展。

关键词: 新型冠状病毒感染后肺纤维化, 肺纤维化, 吡非尼酮, 尼达尼布

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a large number of patients with corona virus disease 2019 (COVID-19) in the world, with the evolution of the disease, the problem of pulmonary fibrosis in some patients after the acute stage has become increasingly prominent. Currently, scholars call it post COVID-19 pulmonary fibrosis (PCPF). Due to the continuous mutation of the virus and different medical levels in different parts of the world, the incidence, diagnosis and treatment of PCPF vary slightly among different studies. The degree of fibrosis significantly affects the clinical manifestations of patients, prolonged symptoms of patients, the need for a large number of medical resources and long-term professional care. At present, the diagnosis of PCPF depends on clinical combination with CT and pulmonary function test (PFT), and the treatment depends on previous treatment experience of other pulmonary fibrosis diseases, and there is a lack of unified and standardized treatment plan. Although many scholars have carried out research for this, there is still no very effective treatment. During this review the pathogenesis and mechanism of PCPF are summarized, and the research progress of related diagnosis and treatment is reviewed.

Key words: Post corona virus disease 2019 pulmonary fibrosis, Pulmonary fibrosis, Pirfenidone, Nintedanib

[1]	George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy[J]. Lancet Respir Med,2020,8(8):807-815.
[2]	Hama Amin BJ, Kakamad FH, Ahmed GS, et al. Post COVID-19 pulmonary fibrosis; a Meta-analysis study[J]. Ann Med Surg (Lond),2022,77:103590.
[3]	Wu X, Liu X, Zhou Y, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study[J]. Lancet Respir Med,2021,9(7):747-754.
[4]	Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, et al. Respiratory function in patients post-infection by COVID-19: a systematic review and Meta-analysis[J]. Pulmonology,2021,27(4): 328-337.
[5]	Tanni SE, Fabro AT, de Albuquerque A, et al. Pulmonary fibrosis secondary to COVID-19: a narrative review[J]. Expert Rev Respir Med,2021,15(6):791-803.
[6]	Saifi MA, Bansod S, Godugu C. COVID-19 and fibrosis: Mechanisms, clinical relevance, and future perspectives[J]. Drug Discov Today, 2022,27(11):103345.
[7]	Lee JH, Koh J, Jeon YK, et al. An integrated radiologic-pathologic understanding of COVID-19 pneumonia[J]. Radiology,2023,306(2):e222600.
[8]	Kostopanagiotou K, Schuurmans MM, Inci I, et al. COVID-19-related end stage lung disease: two distinct phenotypes[J]. Ann Med,2022,54(1):588-590.
[9]	中国研究型医院学会呼吸病学专业委员会, 北京中西医结合学会呼吸病分会. 新型冠状病毒感染引起的肺间质病变诊断和治疗专家建议[J]. 中华结核和呼吸杂志,2020,43(10):827-833.
[10]	Solomon JJ, Heyman B, Ko JP, et al. CT of post-acute lung complications of COVID-19[J]. Radiology,2021,301(2):e383-e395.
[11]	Doğan S, Güldiken GS, Alpaslan B, et al. Impact of COVID-19 pneumonia on interstitial lung disease: semi-quantitative evaluation with computed tomography[J]. Eur Radiol,2023,33(7):4758-4766.
[12]	McGroder CF, Zhang D, Choudhury MA, et al. Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length[J]. Thorax,2021,76(12):1242-1245.
[13]	Liu M, Lv F, Huang Y, et al. Follow-up study of the chest CT characteristics of COVID-19 survivors seven months after recovery[J]. Front Med (Lausanne),2021,8:636298.
[14]	Ball L, Barisione E, Mastracci L, et al. Extension of collagen deposition in COVID-19 post mortem lung samples and computed tomography analysis findings[J]. Int J Mol Sci,2021, 2(14):7498.
[15]	Caruso D, Guido G, Zerunian M, et al. Post-acute sequelae of COVID-19 pneumonia: six-month chest CT follow-up[J]. Radiology,2021,301(2):e396-e405.
[16]	Li X, Shen C, Wang L, et al. Pulmonary fibrosis and its related factors in discharged patients with new corona virus pneumonia: a cohort study[J]. Respir Res,2021,22(1):203-214.
[17]	Cheng D, Calderwood C, Skyllberg E, et al. Clinical characteristics and outcomes of adult patients admitted with COVID-19 in East London: a retrospective cohort analysis[J]. BMJ Open Respir Res,2021,8(1):e000813.
[18]	Trinkmann F, Müller M, Reif A, et al. Residual symptoms and lower lung function in patients recovering from SARS-CoV-2 infection[J]. Eur Respir J,2021,57(2):2003002.
[19]	Mylvaganam RJ, Bailey JI, Sznajder JI, et al. Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection[J]. Eur Respir Rev,2021,30(162):210194.
[20]	廖宝林, 施海燕, 刘艳霞, 等. 新型冠状病毒肺炎患者早期外周血淋巴细胞亚群及细胞因子特征[J/CD]. 中华实验和临床感染病杂志(电子版),2021,15(3):182-188.
[21]	Al-Kuraishy HM, Batiha GE, Faidah H, et al. Pirfenidone and post-COVID-19 pulmonary fibrosis: invoked again for realistic goals[J]. Inflammopharmacology,2022,30(6):2017-2026.
[22]	Sakızcı Uyar B, Ensarioğlu K, Kurt E B, et al. Anti-fibrotic treatment for pulmonary fibrosis induced by COVID-19: A case presentation[J]. Turk J Anaesthesiol Reanim,2022,50(3):228-231.
[23]	Zhou X, Yang D, Kong X, et al. Case report: pirfenidone in the treatment of post-COVID-19 pulmonary fibrosis[J]. Front Med (Lausanne),2022,9:925703.
[24]	Zhang F, Wei Y, He L, et al. A trial of pirfenidone in hospitalized adult patients with severe coronavirus disease 2019[J]. Chin Med J (Engl),2021,135(3):368-370.
[25]	Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis[J]. Eur Respir J,2015,45(5):1434-1445.
[26]	Lamb YN. Nintedanib: A review in fibrotic interstitial lung diseases[J]. Drugs,2021,81(5):575-586.
[27]	Ogata H, Nakagawa T, Sakoda S, et al. Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019[J]. Respirol Case Rep,2021,9(5):e00744.
[28]	Bussolari C, Palumbo D, Fominsky E, et al. Case report: Nintedaninb may accelerate lung recovery in critical coronavirus disease 2019[J]. Front Med (Lausanne),2021,8:766486.
[29]	牟向东, 赵景全. 北京清华长庚呼吸中心重型新冠病毒肺炎简明诊治建议(第一版)[EB/OL]. 2022-12-19. URL
[30]	Myall KJ, Mukherjee B, Castanheira AM, et al. Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment[J]. Ann Am Thorac Soc,2021,18(5):799-806.
[31]	Chen Q, Yang Q, Fang Y, et al. Potential benefits of precise corticosteroid therapy for critical COVID-19[J]. Respir Physiol Neurobiol,2022,297:103813.
[32]	Kostorz-Nosal S, Jastrzębski D, Chyra M, et al. A prolonged steroid therapy may be beneficial in some patients after the COVID-19 pneumonia [J]. Eur Clin Respir J,2021,8(1):1945186.
[33]	Micheletto C, Izquierdo JL, Avdeev SN, et al. N-acetylcysteine as a therapeutic approach to post-COVID-19 pulmonary fibrosis adjunctive treatment[J]. Eur Rev Med Pharmacol Sci,2022,26(13):4872-4880.
[34]	Martinez FJ, de Andrade JA, Anstrom KJ, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis[J]. N Engl J Med,2014,370(22):2093-2101.
[35]	Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis[J]. N Engl J Med,2005,353(21):2229-2242.
[36]	Shi H, Yin D, Bonella F, et al. Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis[J]. BMC Pulm Med,2020,20(1):128-136.
[37]	Sakamoto S, Kataoka K, Kondoh Y, et al. Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial[J]. Eur Respir J,2021,57(1):2000348.
[38]	Heister PM, Poston RN. Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID-19[J]. Pharmacol Res Perspect,2020,8(5):e00653.
[39]	Wu WH, Feng YH, Min CY, et al. Clinical efficacy of tetrandrine in artificial stone-associated silicosis: A retrospective cohort study[J]. Front Med (Lausanne),2023,10:1107967.
[40]	Chen S, Liu Y, Ge J, et al. Tetrandrine treatment may improve clinical outcome in patients with COVID-19[J]. Medicina (Kaunas),2022,58(9):1194.
[41]	Alva R, Mirza M, Baiton A, et al. Oxygen toxicity: cellular mechanisms in normobaric hyperoxia [J]. Cell Biol Toxicol,2023,39(1):111-143.
[42]	Hardinge M, Annandale J, Bourne S, et al. British Thoracic Society guidelines for home oxygen use in adults[J]. Thorax,2015,70(Suppl 1):i1-i43.
[43]	Jacobs SS, Krishnan JA, Lederer DJ, et al. Home oxygen therapy for adults with chronic lung disease. an official american thoracic society clinical practice guideline[J]. Am J Respir Crit Care Med,2020,202(10):e121-e141.
[44]	Meng F, Xu R, Wang S, et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial[J]. Signal Transduct Target Ther,2020,5(1):172-178.
[45]	Shi L, Huang H, Lu X, et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial[J]. Signal Transduct Target Ther,2021,6(1):58-66.
[46]	Bharat A, Machuca TN, Querrey M, et al. Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries[J]. Lancet Respir Med,2021,9(5):487-497.
[47]	Kurihara C, Manerikar A, Querrey M, et al. Clinical characteristics and outcomes of patients with COVID-19-associated acute respiratory distress syndrome who underwent lung transplant[J]. JAMA,2022,327(7):652-661.

[1]	张锐, 沈雅芳, 安肖霞, 林双. 黄芩苷对博来霉素诱导肺纤维化小鼠的保护作用及其机制[J]. 中华危重症医学杂志(电子版), 2020, 13(01): 49-54.
[2]	谢晗, 陈琼, 王懿春. 内皮抑素通过Notch1/血小板源生长因子信号通路对小鼠肺纤维化的抑制作用[J]. 中华危重症医学杂志(电子版), 2019, 12(06): 361-366.
[3]	中华医学会器官移植学分会肺移植学组, 国家肺移植质控中心. 新型冠状病毒感染肺移植受者选择中国专家建议[J]. 中华移植杂志(电子版), 2023, 17(01): 13-16.
[4]	李青原, 冯同, 邱雪琴, 李万成. 迷迭香提取物防治肺纤维化研究进展[J]. 中华肺部疾病杂志(电子版), 2022, 15(06): 908-911.
[5]	王赛妮, 徐旺, 李华娟, 唐英俊, 李卫霞, 李羲, 黄华萍. 影像表现为肺纤维化的肉芽肿性多血管炎一例报告并文献复习[J]. 中华肺部疾病杂志(电子版), 2022, 15(04): 603-605.
[6]	杜文峰, 周玲, 李琪. 血清KL-6对特发性肺纤维化患者诊断及预后的意义[J]. 中华肺部疾病杂志(电子版), 2022, 15(02): 218-220.
[7]	刘雪娇, 盛伟利, 丁艳艳, 尹凤先. 特发性肺纤维化急性加重患者预后危险因素及意义[J]. 中华肺部疾病杂志(电子版), 2022, 15(02): 212-214.
[8]	李佳怡, 王亚菲, 郝月琴, 陈建攸. CXCL14、TGF-β1和CTGF水平与特发性肺纤维化的关系[J]. 中华肺部疾病杂志(电子版), 2021, 14(02): 222-224.
[9]	陈宇平, 朱毅. 特发性肺纤维化与胃食道返流研究进展[J]. 中华肺部疾病杂志(电子版), 2020, 13(04): 551-554.
[10]	孙莹, 宋晓萍, 孙伟. 探讨TGFβ1、PDGF、VEGF对特发性肺纤维化诊断及病情评估的临床意义[J]. 中华肺部疾病杂志(电子版), 2020, 13(01): 54-58.
[11]	张致苍, 雷尚昆. 血清LTBP2作为特发性肺纤维化患者预后标志物的研究[J]. 中华肺部疾病杂志(电子版), 2019, 12(06): 733-737.
[12]	胡新春, 李昌波, 孙杰, 邓超英, 肖华毅, 刘翱. N-乙酰半胱氨酸与IL-27对博莱霉素诱导的小鼠肺纤维化的影响[J]. 中华肺部疾病杂志(电子版), 2019, 12(06): 691-696.
[13]	高菲, 陈娜, 张才擎. microRNA-133a在抗肺纤维化作用中的研究进展[J]. 中华临床医师杂志(电子版), 2021, 15(10): 794-796.
[14]	吕昆明, 王沙沙, 万军, 令狐恩强. 胃食管反流病与特发性肺纤维化关系的研究进展[J]. 中华胃肠内镜电子杂志, 2023, 10(02): 121-124.
[15]	翟胜爽, 雷小红, 赵子锌, 王鹤, 卢林, 孙琳林. 涎液化糖链抗原-6在老年特发性肺纤维化诊治中的应用[J]. 中华老年病研究电子杂志, 2020, 07(02): 26-31.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Progress on diagnosis and treatment of post corona virus disease 2019 pulmonary fibrosis

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Progress on diagnosis and treatment of post corona virus disease 2019 pulmonary fibrosis